Artivion Inc AORT

$23.44 +0.52 (2.27%)

Valuation

Market cap
1,117,488,000
Revenue TTM
$441,330,000
Net income TTM
$9,770,000
PE ratio
42.48
Forward PE
50.98
Profit margin
2.21%
Debt to equity
0.82

Trading

Volume
418,100
Avg volume
575,444
Day's range
$23.05 – $23.80
Shares out
48,756,000
Stochastic %K
71%
Beta
1.23
Analysts
Strong Sell
Price target
$40.91

Price

Company profile

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXU...

Show more

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Industry
Medical Devices
Sector
Healthcare
Phone
770 419 3355
Website
https://artivion.com
Address
1655 Roberts Boulevard NW, Kennesaw, United States

Latest news

Stocktwits

Georgia80 Oct 12, 2:21 AM
$AORT Management reaffirmed full-year guidances..
0 replies
Georgia80 Oct 12, 2:18 AM
$AORT Has Expanded aortic arch product portfolio[.
0 replies
Georgia80 Oct 12, 2:16 AM
$AORT 2 important product lines are growing.
0 replies
Georgia80 Oct 12, 2:15 AM
$AORT FDA approval creates a growth catalyst//
0 replies
Blockwave01 Aug 11, 6:48 PM
$AORT 21 AUG 26 $30 CALL $0.35 GAP FILL PLAY + PRICE UPGRADE
0 replies
Noxtradealerts Aug 11, 6:48 PM
$AORT 21 AUG 26 $30 CALL $0.35
0 replies
StocktwitsEarnings Aug 6, 8:16 PM
$AORT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.28 down -1033.33% YoY • Reported revenue of $125.76M up 11.32% YoY • Artivion reiterates its full year 2026 revenue expectations in the range of $480 to $496 million, with adjusted EBITDA forecasted to be in the range of $92 to $99 million.
0 replies
Estimize Aug 6, 3:01 PM
$AORT reports after the close, Estimize Consensus +0.01 EPS and +1.11M Revs compared to WS http://www.estimize.com/aort/fq2-2026?utm_conten
0 replies